Evidence map›Paper›PMID 40754866›Full record

ReviewCurrent neuropharmacology2025

Advancing Alzheimer's Diagnosis with AI-Enhanced MRI: A Review of Challenges and Implications.

Zahra Batool, ShanShan Hu, Mohammad Amjad Kamal, Nigel H Greig, Bairong Shen

Abstract readReview
In one paragraph

Review in Current neuropharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Zahra BatoolCenter for High Altitude Medicine, Institutes for Systems Genetics, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China.
ShanShan HuCenter for High Altitude Medicine, Institutes for Systems Genetics, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China.
Mohammad Amjad KamalCenter for High Altitude Medicine, Institutes for Systems Genetics, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China.
Nigel H GreigDrug Design & Development Section, Translational Gerontology Branch, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, 21224, USA.
Bairong ShenCenter for High Altitude Medicine, Institutes for Systems Genetics, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China.

Funding

National Natural Science Foundation of China 32270690, 32070671
6 · The paper itself

Abstract

Neurological disorders are marked by neurodegeneration, leading to impaired cognition, psychosis, and mood alterations. These symptoms are typically associated with functional changes in both emotional and cognitive processes, which are often correlated with anatomical variations in the brain. Hence, brain structural magnetic resonance imaging (MRI) data have become a critical focus in research, particularly for predictive modeling. The involvement of large MRI data consortia, such as the Alzheimer's Disease Neuroimaging Initiative (ADNI), has facilitated numerous MRI-based classification studies utilizing advanced artificial intelligence models. Among these, convolutional neural networks (CNNs) and non-convolutional artificial neural networks (NC-ANNs) have been prominently employed for brain image processing tasks. These deep learning models have shown significant promise in enhancing the predictive performance for the diagnosis of neurological disorders, with a particular emphasis on Alzheimer's disease (AD). This review aimed to provide a comprehensive summary of these deep learning studies, critically evaluating their methodologies and outcomes. By categorizing the studies into various sub-fields, we aimed to highlight the strengths and limitations of using MRI-based deep learning approaches for diagnosing brain disorders. Furthermore, we discussed the potential implications of these advancements in clinical practice, considering the challenges and future directions for improving diagnostic accuracy and patient outcomes. Through this detailed analysis, we seek to contribute to the ongoing efforts in harnessing AI for better understanding and management of AD.

Indexed as

Alzheimer DiseaseArtificial IntelligenceBrainMagnetic Resonance ImagingNeuroimagingDeep LearningHumansNeural Networks, ComputerAlzheimer's diseaseArtificial Intelligenceconvolution neural networks (CNNs)deep learning modelsimpaired cognition.magnetic resonance imagingneurodegeneration

Identifiers

PMID40754866
PMCPMC12676019

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.